Our Science
Our Science
Cutting-edge research and technology
Our initiatives
Our initiatives
Campaigning for a smoke-free future
Smoke-Free Life
Smoke-Free Life
Go beyond your past, make a positive change
pmi-emblem

Why Invest in PMI?

We've built the worlds most succesful cigarette company. Now we're building our future on smoke-free products that are much better choices.

$ 8374

0.20 (0.24%)

Investor Relations

Latest Press Releases

Media Center
  • News 08 Nov, 2019

    An unsustainable trade: PMI is supporting the MSC initiative to tackle the problem of illicit cigarettes

  • News 08 Nov, 2019

    Taking responsibility: Why companies considered to be part of the problem should be part of the solution

  • Press Release 04 Nov, 2019

    Philip Morris International Inc. Revises, Only for Manufacturing Restructuring Charges in Germany of $0.20 Per Share, Its 2019 Full-Year Reported Diluted EPS Forecast to at Least $4.53 vs. $5.08 in 2018,

  • News 22 Oct, 2019

    Leaving cigarettes behind: PMI CEO addresses some of the issues around smoke-free products

This site is operated for the purpose of providing general information about us. The site is not operated for advertising or marketing purposes. The material on this site should not be regarded as an offer to sell, or a solicitation of an offer to buy, any product of PMI. Such products are sold only in compliance with the laws of the particular jurisdictions in which they are sold. IQOS and other smoke-free products under development by PMI are not currently available in the U.S. . PMI has now been granted authorization to market IQOS 2.4 in the U.S. from the Food and Drug Administration (FDA), which Altria will bring to the U.S. market under the terms of a license from PMI. The FDA has not yet determined whether IQOS 2.4 meets the standard to be marketed in the U.S. as a modified risk tobacco product. PMI’s applications to the FDA seeking authorization to market IQOSin the U.S. as a modified risk product are currently under review.